Our retrospective analysis explored differences in clinicopathological characteristics and survival in patients with PDA with various oncogenic KRAS allele variants with and without co-occurring PI3K pathway and other genomic alterations. The gene discussed is KRAS; the disease is Patent ductus arteriosus.